B Lymphocyte-Specific c-Myc Expression Stimulates Early and Functional Expansion of the Vasculature and Lymphatics during Lymphomagenesis

American Journal of Pathology

Volumn 163, Issue 6, 2003, Pages 2233-2245

  Ruddell, Alanna ^a,b   Mezquita, Pau ^a   Brandvold, Kimberly A ^a   Farr, Andrew ^a   Iritani, Brian M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYE; MYC PROTEIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BONE MARROW METASTASIS; CANCER CELL; CARCINOGENESIS; CONTROLLED STUDY; GENE EXPRESSION; GENE FUNCTION; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LYMPH FLOW; LYMPH NODE METASTASIS; LYMPH VESSEL; LYMPH VESSEL ENDOTHELIUM; LYMPHATIC SYSTEM; LYMPHOID TISSUE; LYMPHOMA; LYMPHOMAGENESIS; METASTASIS; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; TRANSGENIC MOUSE; VASCULARIZATION;

EID: 0344844551     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63581-X     Document Type: Article

References (47)

1. Schmidt EV: The role of c-myc in cellular growth control. Oncogene 1999, 18:2988-2996
2. Nesbit CE, Tersak JM, Prochownik EV: MYC oncogenes and human neoplastic disease. Oncogene 1999, 18:3004-3016
3. Brandvold KA, Ewert DL, Kent SC, Neiman P, Ruddell A: Blocked B cell differentiation and emigration support the early growth of Myc-induced lymphomas. Oncogene 2001, 20:3226-3234
4. Iritani BM, Eisenman RN: c-Myc enhances protein synthesis and cell size during B lymphocyte development. Proc Natl Acad Sci USA 1999, 96:13180-13185
5. Brandvold KA, Neiman P, Ruddell A: Angiogenesis is an early event in the generation of myc-induced lymphomas. Oncogene 2000, 19: 2780-2785
6. Ngo CV, Gee M, Akhtar N, Yu D, Volpert O, Auerbach R, Thomas-Tikhonenko A: An in vivo function for the transforming Myc protein: elicitation of the angiogenic phenotype. Cell Growth Differ 2000, 11:201-210
7. Pelengaris S, Littlewood T, Khan M, Elia G, Evan G: Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell 1999, 3:565-577
8. Felsher DW, Bishop JM: Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc Natl Acad Sci USA 1999, 96:3940-3944
9. Watson PH, Safneck JR, Le K, Dubik D, Shiu RP: Relationship of c-myc amplification to progression of breast cancer from in situ to invasive tumor and lymph node metastasis. J Natl Cancer Inst 1993, 85:902-907
10. Sato K, Miyahara M, Saito T, Kobayashi M: c-myc mRNA overexpression is associated with lymph node metastasis in colorectal cancer. Eur J Cancer 1994, 30A:1113-1117
11. Riou G, Le MG, Favre M, Jeannel D, Bourhis J, Orth G: Human papillomavirus-negative status and c-myc gene overexpression: independent prognostic indicators of distant metastasis for early-stage invasive cervical cancers. J Natl Cancer Inst 1992, 84:1525-1526
12. Kawashima K, Shikama H, Imoto K, Izawa M, Naruke T, Okabayashi K, Nishimura S: Close correlation between restriction fragment length polymorphism of the L-MYC gene and metastasis of human lung cancer to the lymph nodes and other organs. Proc Natl Acad Sci USA 1988, 85:2353-2356
13. Alitalo K, Carmeliet P: Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 2002, 1:219-227
14. Saaristo A, Karpanen T, Alitalo K: Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene 2000, 19:6122-6129
15. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, Koller C, Estrov Z, O'Brien S, Keating M, Freireich E, Albitar M: Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000, 96:2240-2245
16. Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J: Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphobiastic leukemia. Am J Pathol 1997, 150:815-821
17. Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R, Albini A, Bussolino F, Dammacco F: Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999, 93: 3064-3073
18. Vacca A, Ribatti D, Ruco L, Giacchetta F, Nico B, Quondamatteo F, Ria R, Iurlaro M, Dammacco F: Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Br J Cancer 1999, 79:965-970
19. Kossakowska AE, Hinek A, Edwards DR, Lim MS, Zhang C-L, Breitman DR: Proteolytic activity of human non-Hodgkins lymphomas. Am J Pathol 1998, 152:565-576
20. Vacca A, Ribatti D, lurlaro M, Albini A, Minischetti M, Bussolino F, Pellegrino A, Ria R, Rusnati M, Presta M, Vincenti V, Persico MG, Dammacco F: Human lymphoblastoid cells produce extracellular matrix-degrading enzymes and induce endothelial cell proliferation, migration, morphogenesis, and angiogenesis. Int J Clin Lab Res 1998, 28:55-68
21. Stacker SA, Baldwin ME, Achen MG: The role of tumor lymphangiogenesis in metastatic spread. EMBO J 2002, 16:922-934
22. Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, Banerji S, Huarte J, Montesano R, Jackson DG, Orci L, Alitalo K, Christofori G, Pepper MS: Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 2001, 20:672-682
23. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K, Detmar M: Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001, 7:192-198
24. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, Kubo H, Achen MG: VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001, 7:186-191
25. He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T, Alitalo K: Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst 2002, 94:819-825
26. Kubo H, Cao R, Brakenhielm E, Makinen T, Cao Y, Alitalo K: Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. Proc Natl Acad Sci USA 2002, 99:8868-8873
27. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmiter RD, Brinster RL: The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985, 318:533-538
28. Langdon WY, Harris AW, Cory S, Adams JM: The c-myc oncogene perturbs B lymphocyte development in Eu-myc transgenic mice. Cell 1986, 47:11-18
29. Harris AW, Pinkert CA, Crawford M, Langdon WY, Brinster RL, Adams JM: The Eμ-c-myc transgenic mouse: a model for high-incidence spontaneous lymphoma and leukemia of early B cells. J Exp Med 1988, 167:353-371
30. Beckstead J: A simple technique for preservation of fixation-sensitive antigens in paraffin-embedded tissues. J Histochem Cytochem 1994, 42:8-13
31. Wigle JT, Harvey N, Detmar M, Lagutina I, Grosveld G, Gunn MD, Jackson DG, Oliver G: An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. EMBO J 2002, 21:1505-1513
32. Farr A, Nelson A, Hosier S, Kim A: A novel cytokine-responsive cell surface glycoprotein defines a subset of medullary thymic epithelium in situ. J Immunol 1993, 150:116-1171
33. Brekken RA, Huang X, King SW, Thorpe PE: Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res 1998, 58:1952-1959
34. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, Jain RK, McDonald DM: Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000, 156: 1383-1380
35. Iritani BM, Forbush KA, Farrar MA, Perlmutter RM: Control of B cell development by Ras-mediated activation of Raf. EMBO J 1997, 16: 7019-7031
36. Leppink DM, Bishop DK, Sedmak DD, Henry ML, Ferguson RM, Streeter PR, Butcher EC, Orosz CG: Inducible expression of an endothelial cell antigen on murine myocardial vasculature in association with interstitial cellular infiltration. Transplantation 1989, 48:874-877
37. Nilsson SK, Debatis ME, Dooner MS, Madri JA, Quesenberry PJ, Becker PS: Immunofluorescence characterization of key extracellular matrix proteins in murine bone marrow in situ. J Histochem Cytochem 1998, 46:371-377
38. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ: Vessel cooption, regression, and growth in tumors mediated by angiopoeitins and VEGF. Science 1999, 284:1994-1997
39. Feng D, Nagy JA, Brekken RA, Pettersson A, Manseau EJ, Pyne K, Mulligan R, Thorpe PE, Dvorak HF, Dvorak AM: Ultrastructural localization of the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) receptor-2 (FLK-1, KDR) in normal mouse kidney and in the hyperpermeable vessels induced by VPF/VEGF-expressing tumors and adenoviral vectors. J Histochem Cytochem 2000, 48:545-556
40. Rosenthal RA, Megyesi JF, Henzel WJ, Ferrara N, Folkman J: Conditioned medium from mouse sarcoma 180 cells contains vascular endothelial growth factor. Growth Factors 1990, 4:53-59
41. Park JE, Keller GA, Ferrara N: Vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepitheliaJ extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993, 4:1317-1326
42. Pelengaris S, Khan M, Evan GI: Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 2002, 109:321-334
43. Baudino TA, McKay C, Pendeville-Samain H, Nilsson JA, Maclean KH, White EL, Davis AC, Ihle JN, Cleveland JL: c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev 2002, 16:2530-2543
44. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K: Lymphangiogenesis and cancer metastasis: nature reviews. Cancer 2002, 2:573-583
45. Kaipainen A, Korhonen J, Mustonen T, van Hinsbergh VW, Fang GH, Dumont D, Breitman M, Alitalo K: Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA 1995, 92:3566-3570
46. Valtola R, Salven P, Heikkila P, Taipale J, Joensuu H, Rehn M, Pihlajaniemi T, Weich H, deWaal R, Alitalo K: VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 1999, 154:1381-1390
47. Nagy JA, Vasile E, Feng D, Sundberg C, Brown LF, Detmar MJ, Lawitts JA, Benjamin L, Tan X, Manseau EJ, Dvorak AM, Dvorak HF: Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med 2002, 196:1497-1506